Kadalu dezamizumab ATTR cardiac

Indicated For

ATTR cardiac amyloidosis

About This Medication

Unable to generate patient guide. Based on the available search results, dezamizumab (GSK2398852) is an experimental monoclonal antibody currently in clinical trial phases for AL amyloidosis treatment[2][7]. No FDA-approved prescription assistance program exists for dezamizumab at this time, as the drug has not received marketing approval. The search results reference only a clinical trial (NCT01777243) and research studies, with no information about a manufacturer-sponsored patient assistance program, income thresholds, application procedures, or eligibility criteria. To obtain accurate information about accessing dezamizumab, patients should consult their healthcare provider about clinical trial enrollment or contact the drug's manufacturer directly regarding investigational drug access programs.

Program information last verified: March 30, 2026